Trial Profile
Randomized Phase IIb Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (RCC).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 18 Aug 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 19 Jul 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 19 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.